Coherus BioSciences (CHRS)
(Delayed Data from NSDQ)
$1.64 USD
+0.07 (4.46%)
Updated Jul 19, 2024 04:00 PM ET
After-Market: $1.63 -0.01 (-0.61%) 7:58 PM ET
3-Hold of 5 3
D Value C Growth D Momentum D VGM
Price, Consensus and EPS Surprise
CHRS 1.64 +0.07(4.46%)
Will CHRS be a Portfolio Killer in July?
Zacks Investment Research is releasing its prediction for CHRS based on the 1-3 month trading system that more than doubles the S&P 500.
About Price, Consensus and EPS Surprise
The Price, Consensus and EPS Surprise chart displays the company's stock price along with the consensus estimate and the EPS surprise. Zacks tracks individual sell-side analyst estimates and creates a consensus EPS estimates. The consensus estimate is the average of all the current estimates made available by brokerage analysts. Consensus estimates are more advantageous because they reduce the risk of any single analyst making an incorrect forecast. ZACKS CONSENSUS ESTIMATE = THE AVERAGE OF ALL CURRENT EPS ESTIMATES. EPS Surprise is the difference (expressed as a percentage) between the actual reported quarterly earnings per share (EPS) vs the estimated quarterly EPS. A company that reports $1.10 in actual quarterly EPS vs. $1.00 in estimated quarterly EPS would show a 10% positive EPS surprise. ((Actual EPS - Estimated EPS) / absolute Estimated EPS) *100 = EPS Surprise %.
Zacks News for CHRS
Coherus BioSciences (CHRS) Reports Q1 Loss, Misses Revenue Estimates
Editas Medicine (EDIT) Reports Q1 Loss, Misses Revenue Estimates
CHRS: What are Zacks experts saying now?
Zacks Private Portfolio Services
Inovio Pharma (INO) Stock Rallies 134% in a Month: Here's Why
Coherus (CHRS) Stock Rallies on FDA Nod for Udenyca Onbody
Vericel Corporation (VCEL) Expected to Beat Earnings Estimates: What to Know Ahead of Q3 Release
Other News for CHRS
Coherus BioSciences Announces Divestiture of YUSIMRY (adalimumab-aqvh) in a $40 Million Upfront All Cash Transaction
Coherus Biosciences announces divestiture of YUSIMRY in $40M transaction
Coherus to divest biosimilar against AbbVie’s Humira for $40M
Pfizer: Seriously Undervalued At Peak Pessimism
FibroGen: Two New In-Licensed Oncology Drugs To Carry It Forward